NantKwest doses first patient in Phase 2 Merkel cell carcinoma study


NantKwest (NASDAQ:NK) dosed the first patient in its Phase 2 trial for second- and third-line Merkel cell carcinoma (MCC).

MCC is a rare and aggressive skin cancer that is fatal for the majority of patients who have progressed on, or after, treatment with a checkpoint inhibitor.

The study will assess NantKwest’s off-the-shelf CD16-targeted natural killer cells – in combination with ImmunityBio’s IL-15 superagonist N-803 and Avelumab – in 43 patients who failed all standard-of-care treatments for MCC, including checkpoint therapy.

“With over 70% of patients failing checkpoint inhibitors in solid tumors, it is vital to develop novel and effective therapeutic options,” Dr. Patrick Soon-Shiong, chairman and CEO of NantKwest and ImmunityBio, said in a statement.

“Our combination therapy is designed to activate the innate immune system to create an immunological memory against tumors, resulting in immunogenic cell death,” he added.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.